Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Gossamer Bio, Inc. is a biopharmaceutical company focused on developing therapies for pulmonary hypertension, including PAH and PH-ILD. Its lead candidate, seralutinib, is an inhaled kinase inhibitor targeting pathways involved in vascular remodeling. The company advances clinical trials, collaborates globally, and aims to provide innovative, targeted treatments for high unmet medical needs in rare pulmonary diseases.
This description was generated via AI from an annual report. Updated about 1 year ago.